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Abstract 27 
Atrioventricular nodal reentry tachycardia (AVNRT) is the most common form of regular paroxysmal 28 
supraventricular tachycardia. This arrhythmia affects women twice as frequently as men, and is often 29 
diagnosed in patients below 40 years of age. Familial clustering, early onset of symptoms, and lack of 30 
structural anomaly indicate involvement of genetic factors in AVNRT pathophysiology.  31 
We hypothesized that AVNRT patients have a high prevalence of variants in genes that are highly 32 
expressed in the atrioventricular conduction axis of the heart and potentially involved in arrhythmic 33 
diseases.  34 
Next-generation sequencing of 67 genes was applied to the DNA profile of 298 AVNRT patients and 10 35 
AVNRT family members using HaloPlex Target Enrichment System. 36 
In total, we identified 229 variants in 60 genes; 215 missenses, four frame shifts, four codon deletions, 37 
three missense and splice sites, two stop-gain variants, and one start-lost variant. Sixty-five of these 38 
were not present in the Exome Aggregation Consortium (ExAC) database. Furthermore, we report two 39 
AVNRT families with co-segregating variants. Seventy-five of 284 AVNRT patients (26.4%) and three 40 
family members to different AVNRT probands had one or more variants in genes affecting the sodium 41 
handling. Fifty-four out of 284 AVNRT patients (19.0%) had variants in genes affecting the calcium 42 
handling of the heart. We furthermore find a large proportion of variants in the HCN1-4 genes. We did 43 
not detect a significant enrichment of rare variants in the tested genes. 44 
This could be an indication that AVNRT might be an electrical arrhythmic disease with abnormal sodium 45 
and calcium handling.  46 
 47 
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Introduction 55 
Atrioventricular nodal reentry tachycardia (AVNRT) is a supraventricular tachycardia (SVT), originating 56 
from the atrio-ventricular node (AVN) region 1. It is the most common form of regular paroxysmal 57 
supraventricular tachycardia 2. Women are affected twice as frequently as men, and the fact that this 58 
arrhythmia is often diagnosed in women under 40 years of age suggests a genetic component of the 59 
disease 3,4. The symptoms of SVT are typically related to the sudden occurrence of tachycardia, with 60 
palpitations being the most common symptom, possibly accompanied by chest discomfort, dyspnoea, 61 
anxiety, and light-headedness. Some patients occasionally experience an unregulated drop in blood 62 
pressure at the onset of the tachycardia, resulting in syncope, particularly at high frequency rates and 63 
during prolonged episodes of tachycardia 5.  64 
AVNRT occurs when a reentry circuit forms within or in close proximity to the AV node. Two areas with 65 
diverse electrophysiological conduction properties (termed pathways) have been found implicated in 66 
the reentry circuits in AVNRT patients, the fast pathway and the slow pathway; both located in the right 67 
atrium. These pathways show opposite electrophysiological properties, with respect to conduction 68 
velocity and duration of the refractory period, resulting in different relations between the P wave and 69 
the QRS complex on the electrocardiogram. In both cases, the P wave appearance is negative in leads II, 70 
III, and aVF 6.  71 
The presence of this diversity in the electrophysiological properties in the area around the AVN is 72 
termed dual AV nodal conduction. Dual AV nodal conduction is considered a congenital functional 73 
abnormality developed during cardiogenesis in foetal life 7. In 2000, Lu et al. described the occurrence of 74 
dual AV nodal conduction in monozygotic twins 8. In addition, Hayes et al. described several families 75 
with AVNRT among first-degree-relatives. The authors were also able to induce typical AVNRT and to 76 
demonstrate dual AV nodal conduction in 12 of the 13 studied family members from six different 77 
families 7. A recent study by Michowitz et al. reported a high familial AVNRT prevalence among patients 78 
who underwent radiofrequency ablation 9. These studies indicate that there could be a hereditary 79 
component in the development of AVNRT. Familial clustering, early onset of symptoms, and the lack of 80 
structural anomaly indicate involvement of genetic factors, as seen in other arrhythmias 10. Several 81 
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cardiac arrhythmias have previously been associated with ion channel variants 11, and this may be a 82 
possible pathophysiological mechanism of AVNRT as well. Identifying possible disease causing and 83 
disease modifying genetic variants could potentially reveal new insight in the pathophysiology of AVNRT 84 
and have a role in future diagnosis and risk assessment.  85 
We hypothesized that AVNRT is an ion channel disease, and that AVNRT patients have a high prevalence 86 
of variants in genes, that are highly expressed in the atrioventricular conduction axis of the heart and 87 
are known to be involved in the pathophysiology of other arrhythmic diseases.  88 
  89 
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Subjects and Methods 90 
Study population 91 
Study participants (probands) were identified among patients treated with radiofrequency catheter 92 
ablation at the Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, in the period 93 
from 2010-2012, with an age >18 years and <60 years. Furthermore, 10 relatives of these probands with 94 
a history of AVNRT were included. Upon inclusion a blood sample, a 12 lead ECG, and a cardiac history 95 
were taken and patients were questioned about their family history. 96 
The study conforms to the principles outlined in the Declaration of Helsinki, and was approved by the 97 
Scientific Ethics Committee of Copenhagen and Frederiksberg (Protocol reference number: H-A-2008-98 
004). 99 
 100 
Control group 101 
The control group consisted of 383 healthy men and women between 55 and 75 years of age and 102 
without history of cardiovascular disease or stroke from the Copenhagen Holter Study 12. 103 
The study protocol was approved by the local ethics committee (KF 01 313322, KF 01 25304). 104 
 105 
Target genes 106 
We selected 67 target genes. The genes were selected based on the following criteria: 1) PR interval 107 
associated genes identified by genome-wide association studies (GWAS) 13, 2) genes selected based on 108 
cardiac expression levels 14, 3) plausible genes based on protein function and association with other 109 
arrhythmic diseases. Selected genes are listed in Table 1. 110 
 111 
Next-Generation Sequencing 112 
DNA was extracted from whole blood that had been stored at -80°C using the QIAamp DNA Blood Mini 113 
and Maxi kits (Qiagen, Hilden, Germany). 114 
We developed a custom design based on HaloPlex technology (Agilent Technologies, Inc., Santa Clara, 115 
CA, USA) to perform high-throughput sequencing of the coding regions of 67 genes. 116 
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Next-generation sequencing (NGS) was applied using HaloPlex Target Enrichment System (Agilent 117 
Technologies, Inc., Santa Clara, CA, USA) on 200 ng DNA from the 298 probands and 10 family members 118 
with AVNRT according to the manufacturer’s instructions 15. In brief, patient DNA was fragmented by 119 
endonucleases and hybridized to biotinylated gene specific probes incorporating Illumina paired-end 120 
sequencing motifs and indexed primers. Hybridised molecules were captured by magnetic beads, PCR 121 
amplified, and sequenced with the MiSeq system (Illumina Inc., San Diego, CA, USA). 122 
 123 
Microarray Genotyping 124 
Genotyping was done using Infinium PsychArray BeadChip. This microarray has ~590,000 fixed 125 
markers. SNP calling and QC and was done following Broads Institute’s recommendations. 126 
 127 
In vitro Electrophysiology  128 
See Supplementary. 129 
 130 
Bioinformatics and Data analyses 131 
Raw reads were aligned to reference genome GRCH37.p13/hg19 with Burrows-Wheelers Aligner, after 132 
trimming adapter sequences and filtering for poor quality reads. Genome Analysis Toolkit (GATK) v3.7 133 
was used for indel realignment and base quality recalibration in the targeted regions.  134 
Variants were called with Unifiedgenotyper/GATK v3.7 following the GATK of Broad Institute’s current 135 
guidelines 16, see Figure 1 for bioinformatics pipeline.   136 
For details on settings and filtering steps, see Supplementary Material. 137 
Genotype array data were used to infer ethnicity and relatedness performed in R with R-package 138 
SNPRelate 17, see Supplementary Material. 139 
 140 
Statistical Analyses 141 
We performed a burden test on the targeted genes with ethnically matched and unrelated subjects in 142 
the AVNRT cohort (considered subjects n=284) and the control group (considered subjects n=377). Only 143 
the intersecting region between the two capture kits and exons with sufficient coverage were 144 
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considered in the tests, see Supplementary Figure 1, 2, 3 and Supplementary text. The intersect region 145 
spanned 30 genes, listed in Supplementary Table 7. 146 
Variants with annotation of a putative deleterious impact were included, see Supplementary Table 3 147 
(e.g. missense, codon deletions). Variants tagged as “COMMON” in dbSnp b.141 were excluded.  148 
We performed two rounds of burden testing. First, variants found in the Exome Aggregation Consortium 149 
(ExAC) database with a minor allele frequency (MAF) above 0.5% in any of the ExAC populations were 150 
excluded, second, this threshold was set to 0.1%. The statistical method SKAT-O was applied in the 151 
burden tests, using R package GENESIS 18,19. A Bonferroni corrected p-value < 0.05 was considered 152 
significant. 153 
 154 
Data availability 155 
Data on reported variants are made available to the European Bioinformatics Institute (EBI) database 156 
The European Genome-phenome Archive (EGA) (https://www.ebi.ac.uk/ega/, study accession 157 
EGAS00001002745). 158 
 159 
  160 
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Results 161 
Two-hundred-and-eighty-four patients with a median onset of AVNRT related symptoms at 24 years of 162 
age were included after excluding ethnic outliers and subjects with unreported relatedness (70% 163 
females). Clinical data of the patient population (probands) are shown in Table 2. 164 
We identified 229 variants in 184 patients; 215 missense, four frame shift, four codon deletions, three 165 
missense and splice sites, two stop-gain variants, and one start-lost variant. Sixty-five of these were not 166 
present in ExAC. The results of the NGS are shown in Supplementary Table 4. 167 
 168 
Variants in sodium handling genes 169 
There were 75 out of 284 AVNRT patients (26.4%) and three family members of three different AVNRT 170 
probands who had one or more variants in genes affecting the sodium handling.  171 
We identified variants in SCN3A (n = 3, ENSG00000166257.4), SCN5A (n = 7, ENSG00000153253.11), 172 
SCN10A (n = 16, ENSG00000185313.6), SCN8A (n = 3, ENSG00000196876.9), SCN4A (n = 12, 173 
ENSG00000007314.7), SCN1A (n = 3, ENSG00000144285.11), SCN2B (n = 1, ENSG00000149575.5), and 174 
SCN9A (n = 12, ENSG00000169432.10).  175 
 176 
Variants in calcium handling genes 177 
Fifty-four of 284 AVNRT patients (19.0%) had variants in genes affecting the calcium handling of the 178 
heart. We identified variants in RYR2 (n = 11, ENSG00000198626.11), RYR3 (n = 16, 179 
ENSG00000198838.7), CACNB2 (n = 2, ENSG00000165995.14), ATP2A2 (n = 2, ENSG00000174437.12), 180 
CACNA1C (n = 5, ENSG00000151067.16), CACNA1D (n = 13, ENSG00000157388.9), CACNA1I (n = 7, 181 
ENSG00000100346.13), and CACNA1G (n = 3, ENSG00000006283.13). 182 
 183 
Variants in the HCN1-4 genes 184 
Thirteen AVNRT patients carried variants in the hyperpolarization-activated and cyclic nucleotide-gated 185 
(HCN) channel genes HCN1 (n = 5, ENSG00000164588.4), HCN2 (n = 1, ENSG00000099822.2), HCN3 (n = 186 
5, ENSG00000263324.1), and HCN4 (n = 2, ENSG00000138622.3). 187 
 188 
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Variants in KCNE3 189 
Three variants with a total allele count of four were found in the KCNE3 (ENSG00000175538.6) gene 190 
encoding the voltage-gated potassium channel Kv. 191 
 192 
Family studies 193 
Six families were identified with AVNRT reported in two or more family members. In two of these 194 
families, variants within the 67 screened genes where found (Figure 2). The proband carrying the 195 
c.6010T>C (p.(Phe2004Leu), ENST00000413689) variant in SCN5A and the c.2623C>T (p.(Pro875Ser), 196 
ENST00000435607) variant in SCN4A had a mother with AVNRT who carried the SCN4A variant and a 197 
sister with AVNRT who carried both the SCN5A and the SCN4A variant. Furthermore, the mother and the 198 
sister with AVNRT both carried the RYR3 variant c.3598C>T (p.(Arg1200Cys), ENST00000389232). 199 
The proband carrying the c.233C>T (p.(Thr78Met, ENST00000343849) variant in CAV3 had a mother 200 
with AVNRT who carried the same variant.  201 
For pedigrees of the four AVNRT families without found variants in the 67 screened genes, see 202 
Supplementary Figure 6. 203 
 204 
Electrophysiological characterization of the SCN5A variants c.1381C>T and c.1576C>T 205 
As numerous genetic variations in SCN5A (ENSG00000183873.11), encoding the primary cardiac sodium 206 
channel Nav1.5, have been linked to a number of arrhythmogenic diseases it is likely that malfunction of 207 
Nav1.5 may also play a role in AVNRT. A total of seven variants in SCN5A were found in the 284 AVNRT 208 
patients. Four of these have previously been functionally characterised by patch-clamping and the fifth 209 
has a stop-gain translation impact, indicating a compromised sodium channel function 20,21. 210 
The in vitro electrophysiological characteristics of c.1381C>T (p.(Leu461Val)) and c.1576C>T 211 
(p.(Arg526Cys)) were studied by patch-clamping following transient expression in HEK293 cells (Figure 212 
3). Whole-cell sodium currents from WT and variant channels in response to depolarizing pulses from -213 
70 mV to + 50 mV are shown in Figure 3A. Peak current density was significantly increased for 214 
c.1381C>T (p.(Leu461Val)) but not for c.1576C>T (p.(Arg526Cys)) (Supplementary Table 5). Activation 215 
and inactivation together with time-dependent inactivation (onset of inactivation) and recovery from 216 
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inactivation, as well as sustained current measurements were performed. However, none of these 217 
investigations revealed a difference between wild type and variant channels. 218 
 219 
Burden tests 220 
After exclusion of family members and ethnic outliers the dataset consisted of 284 AVNRT cases versus 221 
377 controls. 222 
There was no significant enrichment of rare variants in the tested genes after adjusting for multiple 223 
testing, see Supplementary Table 6 and 7. 224 
225 
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Discussion 226 
In total, we identified 229 variants in 184 patients; 215 missense, four frame shift, four codon deletions, 227 
three missense and splice sites, two stop-gain variants, and one start-lost variant. Sixty-five of these 228 
were not present in ExAC. 229 
A recent study by Hasdemir et al. found a phenotypic overlap between 17 patients with AVNRT and 230 
Brugada Syndrome (BrS), and following genetic screening recognized a high proportion of sodium 231 
channel variation in this cohort 22. Their findings indicate a possible sodium channel abnormality in 232 
AVNRT patients.  233 
Here we give a descriptive study that characterize the genetic component of AVNRT, with a focus on 234 
variation in SCN5A as affected conduction velocity was considered a possible disease mechanism.   235 
A total of seven variants in SCN5A were found in the 284 AVNRT patients. Four of these have previously 236 
been functionally characterised by patch-clamping and the fifth has a stop-gain translation impact, 237 
indicating a compromised sodium channel function 20,21. In a study on sudden infant death syndrome 238 
(SIDS), Wang et al. described the c.6010T>C (p.(Phe2004Leu), variant in SCN5A to have a gain-of-239 
function effect 21. The c.1019G>A (p.(Arg340Gln) variant in SCN5A has been associated with SIDS 21 and 240 
Long QT Syndrome 3 and has been shown to induce a negative voltage-shift of both steady-state 241 
activation and inactivation together with a reduced time constant for onset of fast inactivation 20. We 242 
performed functional studies on two of the remaining variants. Our functional studies of c.1381C>T 243 
(p.(Leu461Val)) and c.1576C>T (p.(Arg526Cys)) in SCN5A (ENST00000413689) revealed an increased 244 
current density for c.1576C>T, while c.1381C>T was not found to have altered current characteristics on 245 
the parameters tested. Our subsequent principal component analysis (PCA) indicated that the carrier 246 
had a mixed ethnic background (Supplementary Figure 5a) and further analyses of the variant showed a 247 
MAF > 1% within an Afro-American cohort 23 . We identified 16 variants in the SCN10A gene, whereof 248 
four had been functionally characterized in previous studies and the fifth has a stop-gain translation 249 
impact 24,25. 250 
Although functional characterization not equals causality, our results might indicate that altered sodium 251 
current predispose for AVNRT by affecting the conduction velocity due to potential disease modifiers in 252 
sodium handling genes. Independent replication of these results is, however, needed in larger cohorts. 253 
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It is also noteworthy that we identified two loss-of-function (LOF) variants in the KCNE3 gene, which has 254 
only three reported LOF variants in the ExAC database. 255 
It is difficult to conclude on these findings, but nevertheless interesting. 256 
Several studies have found AVNRT in AF patients, and this overlap in arrhythmia phenotype may support 257 
an overlap in disease mechanisms 25–27. This suggested common disease mechanism is supported by the 258 
fact that several studies have demonstrated frequent sodium channel variants in AF patients. The results 259 
from the present study combined with the data by Jabbari et al. who sequenced 225 early-onset lone AF 260 
patients and found 11 patients with rare variants in SCN10A of which three (27%) had an AVNRT 261 
diagnosis as well, despite all of them being diagnosed with AF before the age of 36 25, further supports 262 
the involvement of sodium channels in the pathophysiology of AVNRT.  263 
Some of our AVNRT probands carried variants in the HCN1-4 genes, which all have been found to have a 264 
high intolerance to variation (a positive Z-score up to 7.27 for HCN2 in the ExAC browser 23). The HCN2 265 
and HCN4 genes have previously been associated with sinoatrial nodal dysfunction and the HCN genes 266 
have an important role in the contractility of the heart muscle by restoring the resting membrane 267 
potential in cardiomyocytes from hyperpolarized potentials as well as contributing to the next 268 
depolarization 28. 269 
Interestingly, the c.2623C>T (p.(Pro875Ser), ENST00000435607) variant in SCN4A co-segregated in a 270 
family with three AVNRT patients, a mother and her two daughters, see Figure 2. Traditionally, the 271 
SCN4A gene is not considered a main contributor to the electrophysiology of the heart, but our findings, 272 
although only hypothesis generating, might indicate a role for Nav1.4 in the atria. 273 
One of the challenges with AVNRT is that its definite diagnosis requires invasive electrophysiological 274 
study (EPS) or an oesophageal ECG recording. To obtain the highest degree of correct clinical phenotype 275 
in this study we required that patients had an invasive EPS demonstrating AVNRT and following this the 276 
patients had a radiofrequency catheter ablation performed. By these relatively strong inclusion criteria 277 
we have minimized the risk of misdiagnosis of tachyarrhythmia subtype.  278 
It is important to consider that studies have found an overrepresentation of previously phenotype-279 
associated genetic variants in the general population 29,30. This indicates that some of these genetic 280 
variants might not be monogenic causes of disease. Also, the functional analyses performed in this study 281 
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used a conventional heterologous expression system; hence, the environments differ from that in native 282 
cardiomyocytes. Lastly, as dual AV nodal physiology can be asymptomatic, it would be interesting to test 283 
control subjects for dual AV nodal physiology in a larger study setup. 284 
This is, to our knowledge, the first study where the primary aim was to investigate the genetic 285 
component in AVNRT using a NGS approach. We have given a descriptive report of variants seen in 286 
genes responsible for the sodium of the heart, many of which have been functionally characterized. 287 
Furthermore, we report two AVNRT families with co-segregating variants. Despite of familial clustering, 288 
we are not able to detect a single gene or gene family to be involved with AVNRT, however, we do 289 
report several interesting findings of rare genetic variation in AVNRT. The data suggest that some 290 
patients with AVNRT have genetic variants that can potentially affect sodium handling, possibly by 291 
affecting the conduction velocity and the refractory period. The genetic picture is, however, still 292 
complex, and structural genes might play a larger role in cardiac arrhythmias than previously thought. As 293 
this is only the beginning of the genetic investigation of AVNRT, the need for further genetic studies is 294 
needed. 295 
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Titles and legends to figures 380 
Figure 1. Diagram for the bioinformatics pipeline of sequence data. Data processing starts with raw 381 
reads from the Next-Generation Sequencing.  Reads, alignments, and variant calls are quality 382 
controlled (QC) in intermediate steps. Variants that are of interest for further analyses are obtained 383 
from a high quality genotype set at end of pipeline. 384 
 385 
Figure 2. Pedigrees of the families with found variants and a history of AVNRT. 386 
 387 
Figure 3. Electrophysiological effects of Nav1.5-WT, L461V and R526C on sodium channel current 388 
(INa). Whole-cell patch clamp analyses of transiently transfected HEK-293 cells. A: Representative INa 389 
traces in cells expressing WT or mutants. B: Peak current-voltage relationship measured at -20 mV 390 
for Nav1.5-WT (n=7), L461V (n=10), and R526C (n=7). Currents were normalized to membrane 391 
capacitance. R526C was significantly different from WT (*P <.05). C, D: Voltage dependence of 392 
activation and inactivation for Nav1.5 of the 3 groups, indicating gating properties of channel 393 
conductance and availability. The normalized values have been calculated by dividing the current 394 
level at the respective voltage by the maximal current of the whole voltage range (I/Imax). Boltzmann 395 
curves were fitted to both steady-state activation and inactivation data. Averaged values and the 396 
number of cells used are represented in Supplementary Table 5. E: Time dependent of recovery 397 
from fast inactivation of 3 groups determined using a two-pulse protocol. Data were fitted with a 398 
single exponential equation. Time constants are listed in Supplementary Table 5. The applied 399 
voltage-clamp protocols in inset of the respective figure. Of note, a recovery potential of -80 mV was 400 
applied in order to mimic the resting membrane potential in the human atrial myocytes. F: Sustained 401 
(late) Na+ current as percentage of peak current measured following 330-350 ms depolarisations to -402 
20 mV. G: Onset (decay) of inactivation following depolarising pulses to either -20 mV, 0 mV or 20 403 
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mV. C and D were analysed by Student’s unpaired t-test. E, F and G were analysed by one-way 404 
ANOVA repeated measures with Dunnett’s post-test. 405 
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Gene Ensembl gene id Ref
ARHGAP24 ENSG00000138639.13
CAV1 ENSG00000105974.7
CAV2 ENSG00000105971.10
MEIS1 ENSG00000143995.15
NKX2-5 ENSG00000183072.9
SCN10A ENSG00000185313.6
SOX5 ENSG00000134532.11
TBX3 ENSG00000135111.10
TBX5 ENSG00000089225.15
WNT11 ENSG00000085741.8
ADRB1 ENSG00000043591.4
ADRB2 ENSG00000169252.4
ATP2A2 ENSG00000174437.12
CACNA1C ENSG00000151067.16
CACNA1D ENSG00000157388.9
CACNA1G ENSG00000006283.13
CACNA1I ENSG00000100346.13
DPP6 ENSG00000130226.12
ERG ENSG00000157554.14
GJA1 ENSG00000152661.7
GJA5 ENSG00000143140.6
GJC1 ENSG00000182963.5
GJD3 ENSG00000183153.5
HCN1 ENSG00000164588.4
HCN2 ENSG00000099822.2
HCN3 ENSG00000263324.1
HCN4 ENSG00000138622.3
ITPR1 ENSG00000150995.13
KCNA4 ENSG00000182255.6
KCNA5 ENSG00000130037.3
KCNAB1 ENSG00000169282.13
KCNAB2 ENSG00000069424.10
KCND2 ENSG00000184408.5
KCND3 ENSG00000171385.5
KCNE1 ENSG00000180509.7
KCNJ12 ENSG00000184185.5
KCNJ2 ENSG00000123700.4
KCNJ3 ENSG00000162989.3
KCNJ4 ENSG00000168135.4
KCNJ5 ENSG00000120457.7
KCNQ1 ENSG00000053918.11
NPPA ENSG00000175206.6
PIAS3 ENSG00000131788.11
RYR2 ENSG00000198626.11
(13)
(14)
Table 1. Target genes studied in AVNRT patients
RYR3 ENSG00000198838.7
SCN1A ENSG00000144285.11
SCN1B ENSG00000105711.6
SCN2B ENSG00000149575.5
SCN3A ENSG00000153253.11
SCN3B ENSG00000166257.4
SCN4A ENSG00000007314.7
SCN4B ENSG00000177098.4
SCN5A ENSG00000183873.11
SCN8A ENSG00000196876.9
SCN9A ENSG00000169432.10
SLC8A1 ENSG00000183023.14
AKAP9 ENSG00000127914.12
ANK2 ENSG00000145362.12
CACNB2 ENSG00000165995.14
CASQ2 ENSG00000118729.10
CAV3 ENSG00000182533.6
GPD1L ENSG00000152642.6
KCNE2 ENSG00000159197.3
KCNE3 ENSG00000175538.6
KCNH2 ENSG00000055118.10
NCS1 ENSG00000107130.6
SNTA1 ENSG00000101400.5
†
AVNRT, AV nodal reentry tachycardia. † Plausible genes 
based on protein function and association with other 
arrhythmic diseases. 
Table 2. Clinical data of the AVNRT population.
AVNRT
N 298
Median age at AVNRT associated symptom onset, y (IQR) 24 (11-41)
Female gender, % 70
Height, cm 173 (9)
Weight, kg 76 (16)
BMI 25 (5)
Blood pressure, mmHg
 Systolic 131 (15)
 Diastolic 80 (11)
Smoking, % 22
Syncope, % 14
1st degree relative(s) with cardiac arrhythmia, self-reported, % 30
All data are presented as mean (SD) unless otherwise indicated. AF, atrial fibrillation; 
AVNRT, AV nodal reentry tachycardia; BMI, body mass index (calculated as weight 
[kg] / height2 [m2]; IQR, interquartile range.
